The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | FURTHER: firmonertinib in NSCLC with EGFR PACC mutations
Xiuning Le, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, explores updated results from the Phase Ib FURTHER study (NCT05364073) of firmonertinib in patients with EGFR PACC-mutated non-small cell lung cancer (NSCLC). In first-line metastatic NSCLC, firmonertinib demonstrated promising efficacy, and CNS antitumor activity was also observed. There was a manageable safety profile, with no treatment discontinuations due to adverse events. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
